Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MDLN vs HNGE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HNGE Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 10–0 Matrix Metrics)

HNGE Overall Winner 6-Pillar Tally: MDLN 0 – 6 HNGE Matrix Metrics: MDLN 0 – 10 HNGE

As of Nov 16, 2026, Hinge Health, Inc. (HNGE) is the stronger overall head-to-head candidate over MDLN (MDLN) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MDLN carries a Unified Composite Score of 28.3/100 (SELL) at $39.20 (N/M Forward P/E, N/A operating margin), whereas HNGE carries 39.0/100 (SELL) at $121.04 (35.4x Forward P/E, 18.8% operating margin).

  • Defensive Composite Rating Caution: Although HNGE compares more favorably head-to-head, both MDLN (28.3/100 SELL) and HNGE (39.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MDLN vs HNGE
MDLN US Equity
MDLN
Institutional Equity
$39.20
-0.67% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.81β · 74% Vol
Unified Composite Score
28.3 / 100 SELL
Tech 50.0 Fund 30.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.8% over 20 days), RSI 58
RSI-14: 58.0 · SMA20: $36.60 · SMA50: $35.33
HNGE NYSE Head-to-Head Winner
Hinge Health, Inc.
Services-Computer Processing & Data Preparation
$121.04
+4.9% 1D
Market Cap $9.8B
TTM Revenue $1.43B
Forward P/E 35.4x
Beta / 30D Vol 1.14β · 43% Vol
Unified Composite Score
39.0 / 100 SELL
Tech 10.0 Fund 36.0 Flow 57.0 Mom 31.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (11.4% over 20 days), RSI 62
RSI-14: 61.8 · SMA20: $116.14 · SMA50: $104.43

6-Pillar Scorecard Institutional Category Breakdown (MDLN 0 – 6 HNGE)

Columns: Metric · MDLN · HNGE
1. Valuation Multiples HNGE
Forward P/E N/M 35.4x
Trailing P/E N/M 32.8x
PEG Ratio N/M N/M
EV / Revenue N/M 6.7x
2. Growth & Scale HNGE
Revenue Growth (YoY) N/A +52.4%
Earnings Growth (YoY) N/A -68.4%
TTM Revenue (USD) N/A $1.43B
Market Cap N/A $9.8B
3. Profitability & Quality HNGE
Gross Margin N/A 85.8%
Operating Margin N/A 18.8%
Net Profit Margin N/A 21.0%
Return on Equity (ROE) N/A 47.6%
4. Balance Sheet & Cash Flow HNGE
Cash Generation (TTM) N/A $562M
Cash Flow Margin N/A 39.4%
Net Cash / Leverage N/A ROE $317M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning HNGE
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile N/A (N/A) 55.0% (26th %ile)
Put/Call OI Skew N/A 0.81x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat HNGE
OpEx & R&D Intensity N/A 67.0% of Rev ($956M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Institutional Equity Operator Health Information Services Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MDLN (0) vs HNGE (10)
Institutional Metric MDLN HNGE Criterion Row Edge
Market Capitalization
Scale
N/A $9.8B Larger Scale HNGE
Trailing P/E Ratio
Valuation
N/M 32.8x Lower Multiple HNGE
Forward P/E Ratio
Valuation
N/M 35.4x Lower Multiple HNGE
Revenue Growth (YoY)
Growth
N/A +52.4% Higher Growth HNGE
Operating Margin (TTM)
Profitability
N/A 18.8% Higher Margin HNGE
Net Profit Margin
Profitability
N/A 21.0% Higher Margin HNGE
Return on Equity (ROE)
Capital Efficiency
N/A 47.6% Higher ROE HNGE
52-Week Range Position
Momentum
40% ($31–$51) 94% ($30–$126) Stronger Trend HNGE
Beta / 30D Volatility
Risk Regime
0.81β · 74% Vol 1.14β · 43% Vol Lower Realized Risk HNGE
Unified Institutional Score
Composite Signal
28.3 / 100 (SELL) 39.0 / 100 (SELL) Higher Composite HNGE
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.43B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 85.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 6.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $562M ($317M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HNGE +13.05 pp
MDLN: +9.02% · HNGE: +22.07%
3M Horizon HNGE +22.27 pp
MDLN: +14.9% · HNGE: +37.17%
6M Horizon HNGE +112.4 pp
MDLN: +8.84% · HNGE: +121.24%
1Y Horizon HNGE +154.45 pp
MDLN: -2.6% · HNGE: +151.85%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MDLN vs HNGE. Trailing 12-month operating profitability (MDLN N/A vs HNGE 18.8%) and valuation multiples (MDLN N/M vs HNGE 35.4x Forward P/E) are benchmarked directly in Pillar 4 below.

MDLN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
HNGE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.43B
Gross Margin85.8%
Op. Margin18.8%
ROE / Fwd P/E47.6% · 35.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MDLN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MDLN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
HNGE BREAKOUT
93d in phase · OBV NEUTRAL
Current IV 55.0%
IV Percentile 26th %ile
Put/Call OI Skew 0.81x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact HNGE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MDLN Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
HNGE Moat Profile High-Margin Pricing Power Moat
Health Information Services Operator
Competes within the Health Information Services value chain with $9.8B market capitalization and 18.8% operating margin.
OpEx & R&D Reinvestment 67.0% of Rev ($956M)
90D Engineering Disclosures 0 Published

Investor FAQ MDLN vs HNGE Key Questions & Quantitative Answers

As of Nov 16, 2026, Hinge Health, Inc. (HNGE) is the stronger overall head-to-head candidate over MDLN (MDLN) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MDLN carries a Unified Composite Score of 28.3/100 (SELL) at $39.20 (N/M Forward P/E, N/A operating margin), whereas HNGE carries 39.0/100 (SELL) at $121.04 (35.4x Forward P/E, 18.8% operating margin). Defensive Composite Rating Caution: Although HNGE compares more favorably head-to-head, both MDLN (28.3/100 SELL) and HNGE (39.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

HNGE leads the Growth & Scale pillar: MDLN posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with HNGE at +52.4% YoY revenue growth and -68.4% YoY earnings growth on $1.43B TTM revenue (85.8% gross margin, 18.8% operating margin). On trailing 12-month operating scale, MDLN generates N/A in USD-normalized revenue versus $1.43B for HNGE. In operating R&D and SG&A reinvestment, MDLN deploys N/A (0 90-day corporate R&D disclosures) versus 67.0% of Rev ($956M) (0 disclosures) for HNGE.

HNGE screens cheaper on headline valuation multiples. MDLN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas HNGE trades at 35.4x Forward P/E, 32.8x Trailing P/E, N/M PEG, and 6.7x EV/Revenue (39.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MDLN (N/A ROE) versus HNGE (47.6% ROE) capital efficiency.

In options market volatility and institutional positioning, MDLN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.81β · 74% Vol realized risk). By comparison, HNGE carries 55.0% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.81x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.14β · 43% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.